Cargando…

Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes

BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayer, Wibke, Lietz, Ruth, Ontikatze, Teona, Johrden, Lena, Tenbusch, Matthias, Nabi, Ghulam, Schimmer, Simone, Groitl, Peter, Wolf, Hans, Berry, Cassandra M, Überla, Klaus, Dittmer, Ulf, Wildner, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193818/
https://www.ncbi.nlm.nih.gov/pubmed/21943056
http://dx.doi.org/10.1186/1742-4690-8-75
_version_ 1782213892093509632
author Bayer, Wibke
Lietz, Ruth
Ontikatze, Teona
Johrden, Lena
Tenbusch, Matthias
Nabi, Ghulam
Schimmer, Simone
Groitl, Peter
Wolf, Hans
Berry, Cassandra M
Überla, Klaus
Dittmer, Ulf
Wildner, Oliver
author_facet Bayer, Wibke
Lietz, Ruth
Ontikatze, Teona
Johrden, Lena
Tenbusch, Matthias
Nabi, Ghulam
Schimmer, Simone
Groitl, Peter
Wolf, Hans
Berry, Cassandra M
Überla, Klaus
Dittmer, Ulf
Wildner, Oliver
author_sort Bayer, Wibke
collection PubMed
description BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4(+ )T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4(+ )T cell responses were enhanced by IFNα subtypes. CONCLUSIONS: Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4(+ )T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-retroviral vaccines.
format Online
Article
Text
id pubmed-3193818
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31938182011-10-16 Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes Bayer, Wibke Lietz, Ruth Ontikatze, Teona Johrden, Lena Tenbusch, Matthias Nabi, Ghulam Schimmer, Simone Groitl, Peter Wolf, Hans Berry, Cassandra M Überla, Klaus Dittmer, Ulf Wildner, Oliver Retrovirology Research BACKGROUND: Type I interferons (IFNs) exhibit direct antiviral effects, but also distinct immunomodulatory properties. In this study, we analyzed type I IFN subtypes for their effect on prophylactic adenovirus-based anti-retroviral vaccination of mice against Friend retrovirus (FV) or HIV. RESULTS: Mice were vaccinated with adenoviral vectors encoding FV Env and Gag proteins alone or in combination with vectors encoding IFNα1, IFNα2, IFNα4, IFNα5, IFNα6, IFNα9 or IFNβ. Only the co-administration of adenoviral vectors encoding IFNα2, IFNα4, IFNα6 and IFNα9 resulted in strongly improved immune protection of vaccinated mice from subsequent FV challenge infection with high control over FV-induced splenomegaly and reduced viral loads. The level of protection correlated with augmented virus-specific CD4(+ )T cell responses and enhanced antibody titers. Similar results were obtained when mice were vaccinated against HIV with adenoviral vectors encoding HIV Env and Gag-Pol in combination with various type I IFN encoding vectors. Here mainly CD4(+ )T cell responses were enhanced by IFNα subtypes. CONCLUSIONS: Our results indicate that certain IFNα subtypes have the potential to improve the protective effect of adenovirus-based vaccines against retroviruses. This correlated with augmented virus-specific CD4(+ )T cell and antibody responses. Thus, co-expression of select type I IFNs may be a valuable tool for the development of anti-retroviral vaccines. BioMed Central 2011-09-26 /pmc/articles/PMC3193818/ /pubmed/21943056 http://dx.doi.org/10.1186/1742-4690-8-75 Text en Copyright © 2011 Bayer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bayer, Wibke
Lietz, Ruth
Ontikatze, Teona
Johrden, Lena
Tenbusch, Matthias
Nabi, Ghulam
Schimmer, Simone
Groitl, Peter
Wolf, Hans
Berry, Cassandra M
Überla, Klaus
Dittmer, Ulf
Wildner, Oliver
Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
title Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
title_full Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
title_fullStr Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
title_full_unstemmed Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
title_short Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes
title_sort improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type i interferon subtypes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3193818/
https://www.ncbi.nlm.nih.gov/pubmed/21943056
http://dx.doi.org/10.1186/1742-4690-8-75
work_keys_str_mv AT bayerwibke improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT lietzruth improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT ontikatzeteona improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT johrdenlena improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT tenbuschmatthias improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT nabighulam improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT schimmersimone improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT groitlpeter improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT wolfhans improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT berrycassandram improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT uberlaklaus improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT dittmerulf improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes
AT wildneroliver improvedvaccineprotectionagainstretrovirusinfectionaftercoadministrationofadenoviralvectorsencodingviralantigensandtypeiinterferonsubtypes